Effectiveness of Progesterone in Reducing Preterm Births May Be Altered by Genetic Predisposition
March of Dimes Awards Abstract at SMFM Meeting.
The drug, 17 alpha-hydroxyprogesterone caproate (or 17P), a synthetic form of the progesterone hormone naturally produced during pregnancy, has been demonstrated in clinical trials to prevent some recurrent preterm births – but not all.
“This study helps strengthen the theory that genetic variation in the human progesterone receptor plays an important role in the effectiveness of 17P,” states
Women who have a spontaneous preterm delivery are at greatly increased risk of preterm delivery in subsequent pregnancies. Preterm birth is a leading cause of infant death in
“Dr. Manuck’s research gives us a tantalizing clue as to why 17P works for some women, but not for others,” said
The research, which was sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Unit Network and the
All patients had at least one prior spontaneous preterm birth. The study extracted DNA from the saliva of 389 patients, and then genotyped 20 SNPs in the region of the progesterone receptor gene. Two hundred and fifty-eight (66 percent) of the study participants received 17P and 131 (34 percent) were controls and received a placebo.
Spontaneous preterm birth was less common among women who received 17P. However, after controlling for factors known to be associated with recurrent prematurity, including smoking, number of prior preterm deliveries, and pre-pregnancy body mass index, two SNPs were identified among African-American patients to be predictive of response to progesterone treatment. There was also an interaction between progesterone treatment and genotype of 3 additional polymorphisms for non-African-American women delivering very preterm (less than 32 weeks gestation).
Today’s award-winning study, The Relationship Between Polymorphisms in the Human Progesterone Receptor and Clinical Response to 17 Alpha-Hydroxyprogesterone Caproate for the Prevention of Recurrent Spontaneous Preterm Birth, is the sixth study by SMFM members to be honored by the March of Dimes for innovative research focused on preventing premature births. The March of Dimes is conducting a multi-year, multi-million dollar campaign aimed at using research and awareness to reduce the growing rate of premature birth.
The Society for Maternal-Fetal Medicine (est. 1977) is a non-profit membership group for obstetricians/gynecologists who have additional formal education and training in maternal-fetal medicine. The society is devoted to reducing high-risk pregnancy complications by continuously educating its 2000 members on the latest pregnancy assessment and treatment methods. It also serves as an advocate for improving public policy, and expanding research funding and opportunities for maternal-fetal medicine. The group hosts an annual scientific meeting in which new ideas and research in the area of maternal-fetal medicine are unveiled and discussed. For more information, visit www.smfm.org.
The March of Dimes is the leading nonprofit organization for pregnancy and baby health. With chapters nationwide and its premier event, March for Babies(SM), the March of Dimes works to improve the health of babies by preventing birth defects, premature birth and infant mortality. For the latest resources and information, visit marchofdimes.com or nacersano.org.
SOURCE March of Dimes